Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transgene has enrolled its first patients in a two-step phase II trial with its immunotherapy product candidate TG 1042 to treat relapsing cutaneous B-cell lymphoma (CBCL), a rare malignancy of the skin.
Subscribe to our email newsletter
In the first stage of the trial, a group of 13 patients with relapsing CBCL will be enrolled at centers in the US, France and Switzerland. If the results are positive, a second group of 28 patients will be recruited.
The primary objective of the study is to evaluate the efficacy of a four-month treatment with the drug after standard first line treatments. Patients will receive injections of TG 1042 to induce an anti-tumor immune response. Clinical endpoints are regression and disappearance of lesions, safety and quality of life.
Philippe Archinard, CEO of Transgene, said: “We have strong hopes that, given the increasing need for efficient treatment modalities in this orphan indication, positive results in this trial could lead to regulatory approval in 2009 for a market launch, which would make TG 1042 Transgene's first product to be commercialized.”